ESR1 and neoplasm: In abiraterone/prednisone-treated postmenopausal ER+ advanced BC patients neither the analysis of biomarkers in serum, CTCs nor tumor tissue identified a subgroup a patients with significantly improved PFS, although dual expression of AR and ER in baseline CTCs were supposed to have an association with improved PFS (47).